Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Lgl & Compliance Officer | June 05, 2023 | June 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date June 05, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,398 |
Reported balance
After 2023-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-05 · Sale · Disposed 2,267 · Balance 17,398 F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2: Includes 215 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022. |
| Common StockSEC Table I · non-derivative | Direct | 12,877 |
Reported balance
After 2023-06-06 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-06-06 · Sale · Disposed 4,521 · Balance 12,877 F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
F2: Includes 215 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022.
F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2023 Filed Jun 8, 2023 01:26 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 4,521 | $38.55 | $174,284.55 |
DisclosureSEC source: 0001209191-23-035259 · doc4.xml · nonDerivative · entry 2 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,877 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 05, 2023 Filed Jun 8, 2023 01:26 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,267 | $38.28 | $86,773.96 |
DisclosureSEC source: 0001209191-23-035259 · doc4.xml · nonDerivative · entry 1 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,398 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 215 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 00:04 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 546 | $38.31 | $20,917.26 |
DisclosureSEC source: 0001209191-23-002474 · doc4.xml · nonDerivative · entry 2 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,450 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 04, 2023 Filed Jan 7, 2023 00:04 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 158 | $39.09 | $6,176.69 |
DisclosureSEC source: 0001209191-23-002474 · doc4.xml · nonDerivative · entry 1 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,996 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 204 shares of common stock acquired under the issuer's employee stock purchase plan in December 2022. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 19,900 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035226 · doc4.xml · derivative · entry 5 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,900 Underlying: Common Stock · 19,900 shares Expires 2032-06-08 F6 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 7,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035226 · doc4.xml · nonDerivative · entry 4 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,950 F5 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 23:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,830 | $60.40 | $110,532.00 |
DisclosureSEC source: 0001209191-22-035226 · doc4.xml · nonDerivative · entry 3 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.07 to $60.88, inclusive. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 23:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 740 | $59.38 | $43,941.20 |
DisclosureSEC source: 0001209191-22-035226 · doc4.xml · nonDerivative · entry 2 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,830 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.06 to $60.03, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,980 | $61.37 | $182,894.52 |
DisclosureSEC source: 0001209191-22-035226 · doc4.xml · nonDerivative · entry 1 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,570 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-22-023856 · doc4.xml · derivative · entry 11 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 7,000 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $34.38 | $0.00 |
DisclosureSEC source: 0001209191-22-023856 · doc4.xml · derivative · entry 10 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 Underlying: Common Stock · 2,500 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-22-023856 · doc4.xml · derivative · entry 9 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $40.34 | $0.00 |
DisclosureSEC source: 0001209191-22-023856 · doc4.xml · derivative · entry 8 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,503 | $77.94 | $195,083.82 |
DisclosureSEC source: 0001209191-22-023856 · doc4.xml · nonDerivative · entry 7 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,550 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.585 to $78.490, inclusive. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,937 | $77.03 | $303,267.11 |
DisclosureSEC source: 0001209191-22-023856 · doc4.xml · nonDerivative · entry 6 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,053 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.58 to $77.57, inclusive. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 16,060 | $76.03 | $1,221,041.80 |
DisclosureSEC source: 0001209191-22-023856 · doc4.xml · nonDerivative · entry 5 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,990 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.55 to $76.53, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,000 | $38.35 | $268,450.00 |
DisclosureSEC source: 0001209191-22-023856 · doc4.xml · nonDerivative · entry 4 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,500 | $34.38 | $85,937.50 |
DisclosureSEC source: 0001209191-22-023856 · doc4.xml · nonDerivative · entry 3 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 10,000 | $44.20 | $442,000.00 |
DisclosureSEC source: 0001209191-22-023856 · doc4.xml · nonDerivative · entry 2 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 3,000 | $40.34 | $121,020.00 |
DisclosureSEC source: 0001209191-22-023856 · doc4.xml · nonDerivative · entry 1 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 224 | $63.55 | $14,235.20 |
DisclosureSEC source: 0001209191-22-004198 · doc4.xml · nonDerivative · entry 1 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,550 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 04, 2022 Filed Jan 10, 2022 22:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $61.60 | $0.00 |
DisclosureSEC source: 0001209191-22-002725 · doc4.xml · derivative · entry 2 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-04 F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on December 7, 2022, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| January 04, 2022 Filed Jan 10, 2022 22:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002725 · doc4.xml · nonDerivative · entry 1 MOLLOY ANTHONY · CIK 0001900012 · Chief Lgl & Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,774 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on January 2, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F2 · balance_after: Includes 224 shares of common stock acquired under the issuer's employee stock purchase plan in December 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.